Royce & Associates LP raised its position in CryoPort Inc (NASDAQ:CYRX) by 60.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 220,198 shares of the consumer goods maker’s stock after purchasing an additional 82,998 shares during the quarter. Royce & Associates LP owned 0.78% of CryoPort worth $1,892,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Creative Planning acquired a new position in shares of CryoPort in the fourth quarter worth $5,176,000. Vanguard Group Inc. grew its stake in shares of CryoPort by 96.9% in the second quarter. Vanguard Group Inc. now owns 519,100 shares of the consumer goods maker’s stock worth $2,554,000 after acquiring an additional 255,519 shares in the last quarter. Taylor Wealth Management Partners grew its stake in shares of CryoPort by 5.6% in the fourth quarter. Taylor Wealth Management Partners now owns 415,575 shares of the consumer goods maker’s stock worth $3,570,000 after acquiring an additional 21,935 shares in the last quarter. Allianz Asset Management GmbH acquired a new position in shares of CryoPort in the third quarter worth $1,120,000. Finally, Granite Investment Partners LLC acquired a new position in shares of CryoPort during the third quarter worth $535,000. 22.83% of the stock is currently owned by institutional investors.
Shares of CryoPort Inc (CYRX) traded down $0.40 during trading hours on Wednesday, hitting $9.68. 91,690 shares of the stock were exchanged, compared to its average volume of 121,261. The stock has a market capitalization of $268.75, a PE ratio of -28.49 and a beta of 0.71. CryoPort Inc has a 1-year low of $1.96 and a 1-year high of $10.40.
CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, March 6th. The consumer goods maker reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). CryoPort had a negative return on equity of 47.36% and a negative net margin of 66.09%. The firm had revenue of $3.33 million for the quarter, compared to analysts’ expectations of $3.37 million. CryoPort’s quarterly revenue was up 49.5% compared to the same quarter last year. analysts anticipate that CryoPort Inc will post -0.27 earnings per share for the current year.
CYRX has been the subject of a number of analyst reports. Roth Capital initiated coverage on shares of CryoPort in a research note on Thursday, November 30th. They set a “buy” rating and a $12.50 target price for the company. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price (up previously from $10.00) on shares of CryoPort in a research note on Thursday, March 8th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. CryoPort has an average rating of “Buy” and a consensus price target of $33.70.
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.